Lucas Franki
![1]()
News
Farxiga granted Priority Review for treatment of adults with HFrEF
January 6, 2020
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults with heart failure with reduced ejection fraction based on DAPA-HF.
![1]()
News
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
October 15, 2019
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
![1]()
News
Histologic analysis of vaping-associated lung injury suggests chemical pneumonitis
October 4, 2019
Foamy macrophages and pneumocyte vacuolization were seen in all cases.
![1]()
News
Measles 2019: Most cases occurred in close-knit, undervaccinated communities
October 4, 2019
CDC researcher report on 22 outbreaks in 17 states.
![1]()
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
September 30, 2019
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
August 21, 2019
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
![1]()
News
FDA approves Xenleta for community-acquired bacterial pneumonia treatment
August 20, 2019
The approval was based on results from two trials with a total of 1,289 patients.
![1]()
News
Short-term parenteral antibiotics effective for bacteremic UTI in young infants
August 20, 2019
No significant differences in urinary tract infection recurrence or hospital reutilization between short- and long-term parenteral antibiotic groups.
![1]()
News
CDC updates recommendation for serologic Lyme disease detection
August 15, 2019
The CDC’s updated recommendation is based on the approval of a new test that uses a modified two-test methodology different from the two-test methodology first recommended in 1994.
![1]()
News
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
July 25, 2019
It is the first glucagon therapy approved for this indication that is administrable without an injection.
